Findings

What do systematic reviews say?

3,696 questions · 3,815 findings · 855 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 573 · 15%GRADE not reported 374 · 9.8%Very low 993 · 26%Low 1,062 · 27.8%Moderate 614 · 16.1%High 199 · 5.2%

Opioids vs other analgesics and sedatives

Duration of mechanical ventilation · neonates with mechanical ventilation

1 finding from 1 review

Opioids for newborn infants receiving mechanical ventilation 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Very low

Palivizumab vs Placebo, no intervention or usual care (with or without placebo)

Number of wheezing days · children (0 to 24 months)

Palivizumab leads to lower number of wheezing days compared with placebo, no intervention or standard care (high certainty).

1 finding from 1 review

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children 2021 · Cochrane Headline outcomes only
RR 0.39 [0.35, 0.44]
1 study · 429 participants
High

Blue light vs white light

Surgical complications, serious (up to 90 days; MCID 2%) · patients with non‐muscle invasive bladder cancer

Blue light showed no clear difference in surgical complications, serious (up to 90 days; MCID 2%) compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
RR 0.54 [0.14, 2.14]
1 study · 525 participants
Low

Blue light vs white light

Any adverse events (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer

Blue light showed no clear difference in any adverse events (up to 90 days; MCID 5%) compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
RR 1.09 [0.88, 1.33]
3 studies · 1375 participants
Low

Blue light vs white light

Surgical complications, non‐serious (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer

The review found no eligible studies for this question.

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab vs placebo

Mortality by day 30 · non‐hospitalised individuals with COVID‐19

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 101 participants
Low

Bamlanivimab/etesevimab vs placebo

Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab/etesevimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs placebo

Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs placebo

Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab vs placebo

Mortality by day 60 · non‐hospitalised individuals with COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sotrovimab vs placebo

Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Sotrovimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.33 [0.01, 8.18]
1 study · 583 participants
Low

Sotrovimab vs placebo

Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sotrovimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sotrovimab vs placebo

Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Sotrovimab may leads to lower admission to hospital or death by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.14 [0.04, 0.48]
1 study · 583 participants
Low

Regdanvimab vs placebo

Mortality by day 30Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

Regdanvimab vs placebo

Mortality by day 60Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regdanvimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regdanvimab vs placebo

Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Regdanvimab showed no clear difference in admission to hospital or death by day 30Â compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.45 [0.14, 1.42]
1 study · 204 participants
Low

Regdanvimab vs placebo

Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low